Fujisawa says that it has signed a licensing agreement with Swedish pharmaceutical company, Carlsson Research, for the latter’s anti-psychotic agent, known as ACR-16.

Fujisawa notes that ACR-16 can stabilise the level of the dopamine activity and is a promising agent for the treatment of schizophrenia and neuropsychiatric disorders such as ADHD, Huntington’s disease, Parkinson’s disease and dementia.

Under the terms of the deal, Fujisawa acquires the exclusive rights to develop, manufacture and sell ACR-16 all over the world. However, Carlsson retains the rights to develop and market the product in specific countries as a treatment for Huntington’s disease.